Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 24;13(5):948.
doi: 10.3390/cancers13050948.

Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis

Shoji Kimura  1 , Fumihiko Urabe  1 , Hiroshi Sasaki  1 , Takahiro Kimura  1 , Kenta Miki  1 , Shin Egawa  1
Affiliations
Review

Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis

Shoji Kimura et al. Cancers (Basel). .

Abstract

We performed a systematic review and meta-analysis to assess the prognostic value of prostate-specific antigen (PSA) persistence 4-8 weeks after radical prostatectomy (RP) in patients with prostate cancer, using studies from Medline, Scopus, and Cochrane Library, on 10 October 2020. Studies were eligible if they compared patients with postoperative PSA persistence 4-8 weeks after RP to those without such persistence to assess the value of PSA persistence in prognosticating biochemical recurrence (BCR), disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM) by multivariable analysis. Our review and analysis included nine studies published between 2008 and 2019 with 14,455 patients. Of those studies, 12.0% showed postoperative PSA persistence. PSA persistence was associated with BCR (HR: 4.44, 95% CI: 2.84-6.93), disease recurrence (HR: 3.43, 95% CI: 1.62-7.25), and CSM (HR: 2.32, 95% CI: 1.83-2.95). We omitted meta-analysis on the association of PSA persistence with OM due to an insufficient number of studies. PSA persistence was associated with disease recurrence in a sub-group of patients with pathological nodal involvement (HR: 5.90, 95% CI: 3.76-9.24). Understanding detection of PSA persistence at 4-8 weeks after RP might be useful for patient counseling, follow-up scheduling, and clinical decision-making regarding adjuvant therapies.

Keywords: PSA persistence; meta-analysis; nodal involvement; prostate cancer; recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart for article selection process to analyze the prognostic significance of PSA persistence after radical prostatectomy in patients with prostate cancer.
Figure 2
Figure 2
Forest plots and funnel plots showing the association of PSA persistence with (A) biochemical recurrence, (B) disease recurrence and (C) cancer-specific mortality in Prostate Cancer patients treated with radical prostatectomy.
Figure 3
Figure 3
Forest plot and funnel plot showing the association of PSA persistence with disease recurrence in prostate cancer patients with pathological lymph nodal involvement at radical prostatectomy.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA A Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Gallina A., Chun F.K.-H., Suardi N., Eastham J.A., Perrotte P., Graefen M., Hutterer G., Huland H., Klein E.A., Reuther A., et al. Comparison of stage migration patterns between Europe and the USA: An analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int. 2008;101:1513–1518. doi: 10.1111/j.1464-410X.2008.07519.x. - DOI - PubMed
    1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. [(accessed on 28 October 2020)];2020 Available online: https://uroweb.org/guidelines/
    1. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597. doi: 10.1001/jama.281.17.1591. - DOI - PubMed
    1. Shariat S.F., Kattan M.W., Vickers A.J., Karakiewicz P.I., Scardino P.T. Critical review of prostate cancer predictive tools. Futur. Oncol. 2009;5:1555–1584. doi: 10.2217/fon.09.121. - DOI - PMC - PubMed

LinkOut - more resources